RxDoctor Payments Data

Mariann Harrington, MD

Hematology & Oncology · Little Rock, ARNPI 1184606071

Payments from drug & device makers

$203in general payments, 2019–2025

Across 10 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$60
  • Pfizer$48
  • Daiichi Sankyo Inc.$32
  • Apellis Pharmaceuticals, Inc.$23
  • Pharmacyclics LLC, An Abbvie Company$16
  • Gilead$12
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$4824%
  • Education$15476%

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$203 in reported general payments places this provider in the 10th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$5,836,045
Medicare patients
1,289
Services billed
259,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib86$1,355,855
JakafiRuxolitinib Phosphate31$578,979
Neulasta OnproPegfilgrastim72$447,777
CabometyxCabozantinib S-Malate15$364,839
LenvimaLenvatinib Mesylate15$351,121
IbrancePalbociclib22$343,914
KisqaliRibociclib Succinate16$271,232
TasignaNilotinib Hcl14$262,863
Lanreotide Acetate30$242,752
KeytrudaPembrolizumab19$237,998
TruximaRituximab-Abbs25$170,564
Everolimus21$160,056
Somatuline DepotLanreotide Acetate11$98,871
EliquisApixaban122$88,170
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$69,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$16$1,355,85586 claims
PfizerIbrance, Eliquis$48$432,084144 claims
Johnson & JohnsonXarelto, Procrit$60$95,64975 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →